Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Avoid This Biotech Investment, For Now
Mergers and acquisitions have always been a big part of the biotechnology industry, and the patent cliff has further increased M&A activity.
Posts Tagged ‘NASDAQ:AMGN’
Onyx Pharmaceuticals, Inc. (ONXX) Bidding Wars: Who Would Be the Best Suitor?
Recently, Amgen, Inc. (NASDAQ:AMGN) made a surprisingly low offer to acquire the pharmaceutical company Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).
Immunomedics, Inc. (IMMU), ImmunoGen, Inc. (IMGN): Should You Invest in These Cancer Treatment Biotechs?
Today, cancer is the second leading cause of death in the United States, accounting for nearly a quarter of all deaths in the country.
Quiksilver, Inc. (ZQK), Pfizer Inc. (PFE): Tuesday’s Top Upgrades (and Downgrades)
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Onyx Pharmaceuticals, Inc. (ONXX) Says the Price Isn’t Right
That's the message from Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) over the weekend after Amgen, Inc. (NASDAQ:AMGN) made an unsolicited offer to buy the company.
United Technologies Corporation (UTX), Travelers Companies Inc (TRV): Will These Unlikely Winners Keep Leading the Dow Higher?
After a strong performance during the first half of the year, the Dow Jones Industrials added to its 2013 gains with a 65-point gain.
Amgen, Inc. (AMGN) vs. Big Pharma: It’s Amgen for the Long Term
Over the last three decades I have seen my share of bull and bear markets.
Amgen, Inc. (AMGN)’s Future Is Bright
Amgen, Inc. (NASDAQ:AMGN) has gone up a lot in share price over the last few years. Amgen, Inc.
Three Things That Will Move AbbVie Inc (ABBV) Stock
AbbVie Inc (NYSE:ABBV) has risen more than 20% since it hit the market earlier this year. In fact, it has managed to beat the S&P 500 by nearly 10%.
Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG): Biting Into Biotechnology
Global equity markets have been rocked recently as fears of rising interest rates and tightening monetary possible make their way into the minds of the street.
Amgen, Inc. (AMGN): The Only True Biotech Dividend Stock
Dividend stocks are hard to come by in the biotech space.
Time to Buy Amgen, Inc. (AMGN)?
A double-digit drop for Amgen, Inc. (NASDAQ:AMGN) stock over the past couple of months has likely left a bad taste in the mouths of shareholders.
Biogen Idec Inc. (BIIB), Alexion Pharmaceuticals, Inc. (ALXN): Best-Run Biotech Companies
Which biotech companies are the best-run? That could be a difficult question to answer, since there are many perspectives on what constitutes a well-run company.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Top Treatments for High Cholesterol
About a third of American adults have high LDL cholesterol -- that's the bad kind -- but less than half of adults with high LDL seek treatment, according to the Centers for Disease...
Amgen, Inc. (AMGN): Huge Upside on Pipeline Strength
Amgen, Inc. (NASDAQ:AMGN) is the world’s largest independent biotechnology company.
Gilead Sciences, Inc. (GILD), American International Group, Inc. (AIG): The Biggest Companies That Don’t Pay Dividends — But May Be About To
The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year.
Amgen, Inc. (AMGN), Apple Inc. (AAPL), Coach, Inc. (COH): Three Attractive, Future Dividend Achievers
I regularly browse through a current list of components within the dividend achiever index (companies with 10 or more years of consecutive dividend increases) for new investment...
Dynavax Technologies Corporation (DVAX), Elan Corporation, plc (ADR) (ELN): This Week in Biotech
With the SPDR S&P Biotech Index up 29% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Amgen, Inc. (AMGN), Bristol Myers Squibb Co. (BMY): Ovarian Cancer Drug Half Way There
The biotech giant announced today that its cancer drug trebananib combined with chemotherapy paclitaxel extended median progression-free survival in recurrent ovarian cancer patients...
Two More Good Reasons to Buy Celgene Corporation (CELG)
Celgene Corporation (NASDAQ:CELG) shares have soared more than 46% so far in 2013.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Does This Pipeline Promise Tomorrow’s Blockbuster Sales?
Nearly every big pharma player has been hit with patent expirations that have hit hard on sales lately, and Merck & Co., Inc. (NYSE:MRK) is no exception. Merck & Co., Inc.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Where to Invest for More Health-Care Exposure
You have plenty of choices of where to invest your portfolio.
Regeneron Pharmaceuticals Inc (REGN), Amgen, Inc. (AMGN), Gilead Sciences, Inc. (GILD): Is College Debt a Drag on These Promising Healthcare Stocks
Some stocks seem to have all the luck, offering the best of both worlds.
Amgen, Inc. (AMGN): The Ultimate Biotech Diversification Strategy
You want to invest in biotech. You hear about all the monstrous pops and mini-fortunes that are built overnight.
Amgen, Inc. (AMGN): Insiders Aren’t Crazy About It
Amgen, Inc. (NASDAQ:AMGN) was in 36 hedge funds' portfolio at the end of the first quarter of 2013.
Do Hedge Funds and Insiders Love Celgene Corporation (CELG)?
Celgene Corporation (NASDAQ:CELG) was in 44 hedge funds' portfolio at the end of the first quarter of 2013.
Amgen, Inc. (AMGN) Stock Checkup for May
I have jokingly referred to Amgen, Inc. (NASDAQ:AMGN) in the past as a "senior citizen" of biotech. The company was founded 33 years ago, making Amgen, Inc.
Hedge Funds Are Betting On Gilead Sciences, Inc. (GILD)
To the average investor, there are a multitude of indicators market participants can use to watch stocks.
Amgen, Inc. (AMGN), Bristol Myers Squibb Co. (BMY): Can Financial Innovation Unlock a Cure for Cancer?
A few years ago, Andrew W. Lo from the MIT Sloan School of Management gave a lengthy talk at a meet-and-greet for prospective students of the Master of Finance program.
Amgen, Inc. (AMGN), Johnson & Johnson (JNJ): Boom Or Ticking Time Bomb?
Reaching the coveted $1 billion mark in annual sales is no small feat for a drug.
Amgen, Inc. (AMGN), Duke Energy Corp (DUK), And Where To Find Growth
When a new strategy hits the Street and it gains assets at a significant rate over a very short period of time, the ability of this new program to absorb the new money is quickly...
Amgen, Inc. (AMGN): What’s Its Next Catalyst?
Amgen, Inc. (NASDAQ:AMGN) stock has been on a bit of a roller coaster lately.
Amgen, Inc. (AMGN), Cytokinetics, Inc. (CYTK): A New Approach to Treating a Broken Heart
A failing heart is a lot like a glass Heinz Ketchup bottle. Squeezing the bottle isn't very efficient, so you smack that strategically placed '57,' and still no condiment. ...
Amgen, Inc. (AMGN): Is It a Buy Now?
When it comes to biotechs, Amgen, Inc. (NASDAQ:AMGN) qualifies for the senior citizen discount.
Amgen, Inc. (AMGN): Can Earnings Keep It Soaring?
On Tuesday, Amgen, Inc. (NASDAQ:AMGN) will release its latest quarterly results.
Amgen, Inc. (AMGN): Is It Too Hot to Handle?
Shares of Amgen, Inc. (NASDAQ:AMGN) have returned over 65% in the past year; 109% if dividends are included. The S&P 500 has returned just over 13%.
Under The Hood: An Unheralded Biotech ETF – iShares NASDAQ Biotechnology Index (IBB)
Another day, another set of fresh all-time highs for the major biotechnology ETFs.
Amgen, Inc. (AMGN), Regeneron Pharmaceuticals Inc (REGN), NPS Pharmaceuticals, Inc. (NPSP): Can These Biotechs Continue to Climb?
Two high-flying biotech stocks of late are NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) .
Biopharma News: Theravance Inc (THRX), VIVUS, Inc. (VVUS), Amgen, Inc. (AMGN)
Editor's Note: Related tickers: Theravance Inc (NASDAQ:THRX), VIVUS, Inc. (NASDAQ:VVUS), Amgen, Inc.
Amgen, Inc. (AMGN), Celgene Corporation (CELG) & More Biotech Madness!
March Madness is well under way with the Final Four taking place this weekend.
Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Can It Field a Psoriasis Blockbuster?
Targeting psoriasis, rheumatoid arthritis, and other immune diseases has created some massive markets over the last decade.
Rigel Pharmaceuticals, Inc. (RIGL): Why This Stock Is Poised to Bounce Back
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage drug development company ...
Amgen, Inc. (AMGN): The One Biotech Stock Buffett Should Buy
The biotechnology sector can be a land of immense spoils and incredible heartbreak.
Johnson & Johnson (JNJ): This Company’s Biggest Drug Rivals
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Bristol Myers Squibb Co. (BMY), Amgen, Inc. (AMGN): Tackling Cancer: Melanoma’s Biggest Current & Upcoming Players
As I noted five weeks ago, cancer statistics are both staggering and disappointing.
Is Amgen, Inc. (NASDAQ:AMGN) Going to Burn These Hedge Funds?
Amgen, Inc. (NASDAQ:AMGN) was in 28 hedge funds' portfolio at the end of the fourth quarter of 2012.
Amgen, Inc. (AMGN), Affymax, Inc. (AFFY): The Danger of the One-Hit Wonder
The drug development field is a potentially lucrative, although always dangerous area for small companies and their investors to participate in.
